Xeris Pharmaceuticals (XERS) Updates 2023 Outlook

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced that, in connection with investor meetings the Company is planning to conduct next week in San Francisco, it has updated its outlook for full year 2023. The Company expects to be cashflow positive in the fourth quarter, report total revenue at the top of its previous guidance of $160 million to $165 million and end 2023 with more than $72 million of cash, cash equivalents, and short-term investments, which is above the previously announced guidance of $65 million to $70 million.

“With strong performance across our three commercial products, driving value from our various partnerships, coupled with disciplined expense management, we expect to generate positive cash flow in the fourth quarter, ending 2023 with over $72 million in cash. Our very healthy balance sheet demonstrates our ability to be a self-sustaining enterprise,” said Paul R. Edick, Xeris’ Chairman and CEO. “Looking ahead, we anticipate 2024 total revenue to grow from 2023 levels, operating expenses to remain relatively flat, burn rate continues to decline from 2023 and, we will end 2024 with enough cash to fund our company, meet our obligations, and continue to invest in the growth of the enterprise. We will provide more specific full-year 2024 financial guidance in March when we report fourth quarter and full-year 2023 results.”

You May Also Be Interested In

• ACRES Commercial Realty says labor dispute is hindering hotel sale
• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Profusa reports Q2 2026 loss, advances G3 Vision Labs deal